Credit Suisse initiates coverage on Azul (NYSE:AZUL) with a Outperform rating.
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics – 1-for-18 Reverse Stock Split
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy, 1-for-18 reverse stock split.